| Document |
Document Title |
|
WO/2023/014999A1 |
A method for preparing an 18F-labeled imaging agent comprising a conjugate of a peptide having a binding specificity for programmed death ligand 1 (PD-L1) and a chelating moiety, and optionally a linker. In representative aspects, the 18...
|
|
WO/2023/015322A1 |
The invention provides compositions and methods for treating cancers and proliferative disorders, including solid tumor cancers and non-myeloid hematological malignancies, using radioconjugates targeting CD33, alone or in combination wit...
|
|
WO/2023/014119A1 |
The present invention relates to a novel compound comprising an ester group and uses thereof and, more particularly, to a novel compound that exhibits excellent visualization ability in a tumor by using the difference in activity of este...
|
|
WO/2023/006047A1 |
A sealing apparatus (10, 10'), comprising a sealing base plate (1, 1'), pressing parts (2, 2'), and a sealing turntable (3, 3'), wherein a plurality of pressing parts are enclosed at one end to form a shrink hole (101, 101'), and the sea...
|
|
WO/2023/008556A1 |
The purpose of the present invention is to provide a drug which specifically binds to PSMA, which is effective in treatment and diagnosis of tumors or cancers that express PSMA, such as treatment and diagnosis of prostate cancer, especia...
|
|
WO/2023/006748A1 |
The present invention is based on the finding that Netrin-(1) is retained in a stickier manner in the cell matrix at the cell periphery of the cancer cells, whereas Netrin-(1) is expressed in adults specifically in some tumors. It is als...
|
|
WO/2023/007256A1 |
The present invention provides an improved method of PET imaging in a subject for diagnosis and/or treatment of cardiovascular related disease. The method comprises exponential function dosing based on subject body habitus. It provides i...
|
|
WO/2023/009189A1 |
Provided are compositions and methods for treating cancers and precancerous proliferative disorders in a mammalian subject that involve the combination use of a radiotherapeutic agent, such as a radiolabeled CD33, DR5, 5T4, HER2, HER3, o...
|
|
WO/2023/001317A1 |
Disclosed in the present invention are an acid-responsive nano-micelle on the basis of the Cherenkov effect, and a preparation method and use therefor. The nano-micelle uses pyropheophorbide a as the photosensitizer main body, and modifi...
|
|
WO/2023/002045A1 |
The present invention is related to a compound of Formula (I).
|
|
WO/2023/001004A1 |
The present invention relates to the technical fields of radiopharmaceutical chemistry and clinical nuclear medicine, and in particular to a mannose derivative and an application thereof. The mannose derivative is an isonitrile-containin...
|
|
WO/2023/287686A1 |
The present invention relates to labeled compounds suitable for positron emission tomography (PET) imaging and/or fluorescence imaging such as near-infrared fluorescence imaging (NIRF). The invention further relates to the use of these c...
|
|
WO/2023/283732A1 |
There is described herein a bilayer nanovesicle comprising porphyrin-phospholipid conjugate and a chelator-fatty acid conjugate; wherein the chelator-fatty acid conjugate comprises an aminopolycarboxylic acid conjugated to a single chain...
|
|
WO/2023/287857A1 |
A system for low-count quantitative single-photon emission computed tomography (LC-QSPECT) is provided. The system is programmed to a) store a computer tomography (CT) scan of a subject being examining including a plurality of defined vo...
|
|
WO/2023/282769A1 |
The present invention relates to MOFs for use in radiotherapy. More particularly, the invention provides a particle comprising a MOF, optionally at least one targeting moiety and at least one radionuclide; a composition comprising said p...
|
|
WO/2023/277144A1 |
The present invention provides: a humanized antibody capable of binding to HEG1 protein; and a complex of the antibody and a radioactive nuclear species. According to the present invention, a complex comprising an antibody and a radioact...
|
|
WO/2023/278592A1 |
PARP inhibitor conjugates, including radiolabeled PARP inhibitor conjugates, and methods of treating cancer using the same.
|
|
WO/2023/275195A2 |
Subject matter of the present invention is a lyophilized kit formulation for the preparation of radiometal labeled chelate-functionalized GRP receptor targeting conjugates comprising • a chelate-functionalized GRP receptor targeting co...
|
|
WO/2022/272268A1 |
In one aspect, the present disclosure relates to an imaging agent comprising a detectable moiety covalently bound or coordinated to a "Moiety A" selected from a peptide, a chelator, or an organic compound comprising a leaving atom or a l...
|
|
WO/2022/267097A1 |
A polypeptide targeting integrin α6 and the use thereof. The polypeptide has a sequence motif of RWYD, and is stronger in affinity, wherein the equilibrium dissociation constant KD reaches the level of nM, and the affinity is greatly im...
|
|
WO/2022/269446A1 |
A substance which regulates immune-checkpoints for use as a medicament for treatment of a tumor of a patient wherein the administration pattern of the medicament comprises administering a therapeutically effective amount of the substance...
|
|
WO/2022/270143A1 |
The present invention provides a novel compound which can have the property of being specifically taken into cancer cells. Produced in the present invention is a novel 4-borono-phenylalanine derivative, a borono-phenylalanine derivative ...
|
|
WO/2022/268225A1 |
Provided is a CD8α binding polypeptide. The CD8α binding polypeptide contains at least one variable domain, and compared with an amino acid sequence as represented by SEQ ID NO:1, the amino acid sequence of the variable domain has subs...
|
|
WO/2022/269445A1 |
A vascular inhibitor for use as a medicament for treatment of a tumor of a patient wherein the administration pattern of the medicament comprises administering a therapeutically effective amount of the vascular inhibitor to the patient, ...
|
|
WO/2022/266476A1 |
An irradiation target for the production of radioisotopes, having at least one plate defining a central opening, and a first elongated central member passing through the central opening of the at least one plate so that the at least one ...
|
|
WO/2022/263592A1 |
Provided is a method of preparing an aqueous ascorbic acid solution having a pH of 2.0 to 4.0, the method comprising: providing an initial aqueous solution of ascorbic acid and a base, wherein the initial solution has a pH of 5.0 to 8.0;...
|
|
WO/2022/261771A1 |
The present invention relates to a combination comprising a neurotensin receptor binding compound, gemcitabine and nab-paclitaxel for use for the treatment of a neurotensin receptor overexpressing tumour in a subject.
|
|
WO/2022/263594A1 |
The invention relates to a method of preparing an [18F]radio-labelled compound, wherein the water content is controlled. Controlling the water content and the origin of the water within the reaction process has a significant effect on bo...
|
|
WO/2022/265092A1 |
The present invention addresses the problem of providing a treatment method that is more practical than currently reported methods in cancer treatment using sodium iodide symporter (NIS)-MSCs, and a composition for cancer treatment that ...
|
|
WO/2022/266499A1 |
Conjugates that include two or more chelators (e.g., a chelator of a radiotherapy isotope and a chelator of an imaging isotope) covalently attached to one or more binding moieties are provided herein. The conjugates can be used for treat...
|
|
WO/2022/266487A1 |
An irradiation target system having an irradiation target with at least one annular plate defining a central opening and including an elongated body, a flange portion, and a tab portion, wherein the flange portion extends beyond a first ...
|
|
WO/2022/261770A1 |
The present invention relates to a combination comprising a neurotensin receptor binding compound and FOLFIRINOX for use for the treatment of a neurotensin receptor overexpressing tumour in a subject.
|
|
WO/2022/263595A1 |
Provided is a method of preparing a vial containing an ascorbic acid solution, the method comprising: providing an aqueous solution of ascorbic acid and a base, wherein the solution has a pH of 5.0 to 8.0; degassing the solution with an ...
|
|
WO/2022/259168A1 |
A method for treating a tumor, comprising identifying a tumor as a pancreatic cancer tumor and implanting in the tumor identified as a pancreatic cancer tumor, as least one diffusing alpha-emitter radiation therapy (DaRT) source (21) wit...
|
|
WO/2022/259167A1 |
A method for treating a tumor, comprising identifying a tumor as a colorectal cancer tumor and implanting in the tumor identified as a colorectal cancer tumor, as least one diffusing alpha-emitter radiation therapy (DaRT) source (21) wit...
|
|
WO/2022/261221A1 |
Described herein are non-peptide drug conjugates (NPDCs) that target tumor cells expressing cell surface peptide and protein G protein-coupled receptors and their use in the treatment and/or diagnosis of cancer.
|
|
WO/2022/259173A1 |
A method for treating a tumor, comprising identifying a tumor as a prostate cancer tumor and implanting in the tumor identified as a prostate cancer tumor, as least one diffusing alpha-emitter radiation therapy (DaRT) source (21) with a ...
|
|
WO/2022/259170A1 |
A method for treating a tumor, comprising identifying a tumor as a glioblastoma tumor and implanting in the tumor identified as a glioblastoma tumor, as least one diffusing alpha-emitter radiation therapy (DaRT) source (21) with a suitab...
|
|
WO/2022/259169A1 |
A method for treating a tumor, comprising identifying a tumor as a squamous cell carcinoma tumor and implanting in the tumor identified as a squamous cell carcinoma tumor, as least one diffusing alpha-emitter radiation therapy (DaRT) sou...
|
|
WO/2022/259171A1 |
A method for treating a tumor, comprising identifying a tumor as a breast cancer tumor and implanting in the tumor identified as a breast cancer tumor, as least one diffusing alpha-emitter radiation therapy (DaRT) source (21) with a suit...
|
|
WO/2022/259172A1 |
A method for treating a tumor, comprising identifying a tumor as a melanoma tumor and implanting in the tumor identified as a melanoma tumor, as least one diffusing alpha-emitter radiation therapy (DaRT) source (21) with a suitable radon...
|
|
WO/2022/259166A1 |
A method for treating a cancerous tumor, by implanting in the cancerous tumor at least one diffusing alpha-emitter radiation therapy (DaRT) source (21) with a suitable radon release rate and for a given duration, such that the source (21...
|
|
WO/2022/258637A1 |
The invention relates to a radiotracer labelling precursor having the structure (I) comprising a first target vector (TV1), a second target vector (TV2), a labelling group (MG) for complexation or covalent binding of a radioisotope, a fi...
|
|
WO/2022/260483A1 |
The 18F-ApoPep-7 of chemical formula 1 according to the present invention, which is a derivative of 18F-ApoPep-1, has the manufacturing advantage of labeling the radioisotope F-18 with high radiochemical yield, radiochemical purify, and ...
|
|
WO/2022/261284A1 |
The present invention relates to a composition comprising solid crystalline, non-impact or non-detonation sensitive particles comprising 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone (ABDNAZ), methods of preparing the crystalline form, an...
|
|
WO/2022/255915A1 |
The compounds of the invention are ASEM analogs with different ortho- and para-substitutions that can be labelled with 3H and/or 11C to be used as PET radiotracers capable of binding to α7-nAChR both in vitro and in vivo in a subject bo...
|
|
WO/2022/253785A2 |
The present invention relates to diagnosis and treatment of malignancies characterised by prostate-specific membrane antigen (PSMA) expression. The invention particularly relates to improved radiopharmaceuticals which selectively bind to...
|
|
WO/2022/251496A1 |
The present technology provides compounds, as well as compositions including such compounds, useful in targeted radiotherapy of cancer and/or mammalian tissue overexpressing e.g., a glypican-3 (GPC3) receptor and/or prostate specific mem...
|
|
WO/2022/246511A1 |
The present disclosure relates to cell penetrating anti-DNA antibodies conjugated to a payload and methods of delivering these antibody conjugates to the brain. Compositions comprising these antibody conjugates may be useful for detectin...
|
|
WO/2022/249089A1 |
Embodiments of the present invention provide compositions and methods for the treatment of cancer, in particular prostate cancer. According to certain embodiments, a method of treating cancer in a patient comprises administering to the p...
|
